|Link Technology, Inc.
16 E. Rowan Street, Suite 110
Raleigh, NC 27609-5750
Ph: (919) 881-2121
Fax: (919) 881-2138
Dr. Constance F.
Neely, Founder, CEO, Chief Technology Officer
Donald H. Wilson III, President, COO
Dr. Charles Sanders, Chairman of the Board
Product Line or Service Link Technology, Inc. intends to
focus on its current and near-term research and development efforts to produce the
- Endotoxin tests for research and industrial use
- Endotoxin tests for clinical diagnostic use
- Therapies to prevent organ injury induced by endotoxin and ischemia-reperfusion
Technology/Proprietary Rights Link proprietary technologies are
based on the following patent and patent applications:
- U.S. Patent for "Compositions and methods for the prevention and treatment of
ischemia-reperfusion organ injury" (4/96).
- International patent (PCT)/(USCIP) for "Prevention and treatment of
ischemia-reperfusion and endotoxin related injury using adenosine and purino receptor
Patents allowed, but not yet issued:
- U.S. patent for "Methods and kits for the detection of endotoxin" (1/98)
- U.S. patent for "A1 adenosine antagonist
Patent applications filed:
- U.S. patent for "Methods and compositions for treating and diagnosing tumors"
- U.S. patent for "Compositions and methods for use in ischemia-reperfusion and
endotoxin-related tissue injury""(1/98)
- U.S. patent for "Methods and compositions for the prevention and treatment of
fibrosis and sclerosis" (1/98)
Market Opportunities The market size for Links current product development
is estimated at $6 billion. The markets vary by product. The primary markets for
Links endotoxin tests for research and industrial use are academic and
pharmaceutical R&D laboratories and pharmaceutical and medical device manufacturers.
The primary markets for Links endotoxin tests for clinical diagnostic use are
physicians in their offices, clinics, and hospitals where early detection and monitoring
of gram negative bacterial infection is vital to appropriate patient treatment and
Marketing/Sales and Distribution Link will establish worldwide
marketing channels through licensing, OEM and distribution relationships with leading
pharmaceutical, medical device, and clinical instrumentation companies to capture
significant market share.
Competition The major competition for Links endotoxin
tests for research and industrial use are Associates of Cape Cod, Inc. (recently purchased
by Seikagaku) and Bio Whittaker (recently purchased by Cambrex Corp.).
At the present time, Link knows of no competitors for its endotoxin tests for clinical
diagnostic use. It knows of no company that has produced or is developing a clinical
diagnostic test that can quantitatively detect endotoxin in bodily fluids.
Link believes that its patented technology and approach for its therapies to prevent
damage induced by endotoxin will be superior to methods used by its competition which may
include Alpha Beta Technologies, Bayer, Hoescht-Roussel, RIBI Immunochem, Xoma, and a host
of other companies who will attempt to provide therapies to remedy the serious nature of
septicemia. Link knows of no approach that would represent an effective competitive
alternative to its proprietary and patented technology.
Manufacturing Link will employ the services of custom
manufacturers and develop strategic alliances with established diagnostic and
pharmaceutical companies for its manufacturing.